


## S

### Human Anti-SARS-CoV-2 Spike-RBD Tixagevimab (AZD8895) Neutralizing mAb

|                                 |   |                  |                           |
|---------------------------------|---|------------------|---------------------------|
| <b>Catalog No.</b>              | CPC537A<br>CPC537B<br>CPC537C   | <b>Quantity:</b> | 50 µg<br>100 µg<br>1.0 mg |
| <b>Alternate Names:</b>         | Spike glycoprotein, S glycoprotein receptor binding domain, S-RBD AZD8895, Tixagevimab, COV2-2196   |                  |                           |
| <b>Description:</b>             | <p>Tixagevimab (AZD8895 or COV2-2196) was derived from B-cells donated by convalescent patients after SARS-CoV-2 viral infection. AZD8895 is able to block the binding of the SARS-CoV-2 virus to host cells and protect against infection in cell and animal models of disease.</p> <p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). The structural proteins of SARS-CoV-2 include the envelope protein (E), spike or surface glycoprotein (S), membrane protein (M) and the nucleocapsid protein (N). Spike glycoprotein is cleaved into the following 3 chains, Spike protein S1, Spike protein S2, Spike protein S2'. Spike protein S1 attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Spike glycoprotein is an important target for vaccine development, antibody therapies and diagnostic antigen-based tests.</p> |                  |                           |
| <b>UniProt ID:</b>              | P0DTC2  |                  |                           |
| <b>Origin:</b>                  | Derived from B-cells donated by a convalescent patient after SARS-CoV-2 viral infection   |                  |                           |
| <b>Specificity:</b>             | Recognizes SARS-CoV-2 Spike-RBD protein   |                  |                           |
| <b>Source:</b>                  | XtenCHO   |                  |                           |
| <b>Purity:</b>                  | > 95% by reduced and non-reduced SDS-PAGE   |                  |                           |
| <b>Isotype:</b>                 | Human IgG   |                  |                           |
| <b>Clone:</b>                   | AZD8895 (Tixagevimab ) or COV2-2196   |                  |                           |
| <b>Concentration:</b>           | 1.0 mg/ml, lot specific   |                  |                           |
| <b>Formulation:</b>             | Sterile-filtered PBS, pH 7.5 preservative free.   |                  |                           |
| <b>Purification:</b>            | Protein A affinity chromatography   |                  |                           |
| <b>Applications:</b>            | <b>Neutralization, Functional Assays, ELISA</b>   |                  |                           |
| <b>Storage &amp; Stability:</b> | Stable at 2-8°C for 1 week or for up to 1 year at -20°C to -80°C. It is recommended to prepare single-use aliquots of undiluted product and store -20°C to -80°C. <b>Avoid repeated freeze/thaw cycles.</b>   |                  |                           |





Coomassie blue staining non-reduced and reduced SDS-PAGE analysis

**NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.**



**Cell Sciences®**  
65 Parker Street  
Unit 11  
Newburyport, MA 01950

Toll Free: 888-769-1246  
Phone: 978-572-1070  
Fax: 978-992-0298

E-mail: [info@cellsciences.com](mailto:info@cellsciences.com)  
Website: [www.cellsciences.com](http://www.cellsciences.com)